Michael Winlo

Dr Winlo has a leadership experience across the biotechnology, pharmaceutical and technology sectors. He is currently Chief Executive Officer and Managing Director of Emyria Limited (ASX:EMD), a clinical drug development company, as well as a Non-Executive Director of Nanoveu Limited (ASX:NVU), a company specialising in protective films and coatings. Dr Winlo also serves as a Director and former CEO of Linear Clinical Research, a world-class provider of early and late-stage pharmaceutical trial facilities and management services. Prior to his role at Linear, Dr Winlo was based in Silicon Valley for five years as the Health Lead at Palantir Technologies (NYSE:PLTR).

Companies and Roles

Company
Title
Tenure
Since
EMD
Emyria Limited
  • Managing Director
4yrs, 3mthNov 2019
DVL
Dorsavi Ltd
  • Non-Executive Director
4mthOct 2023
NVU
Nanoveu Limited
  • Non-Executive Director
10mthMar 2023

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
EMD
Emyria Limited
22/12/23646,519282,2227,143,259N/A
DVL
Dorsavi Ltd
25/10/230N/AN/AN/A
NVU
Nanoveu Limited
16/06/23346,154N/A173,077N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
EMD
Emyria Limited
22/12/23
Buy
100,000$0.051$5,070On-market trade
EMD
Emyria Limited
05/10/23
Issued
32,148$0.069$2,218Rights issue
EMD
Emyria Limited
05/10/23
Issued
64,297$0.075$4,822Rights issue
EMD
Emyria Limited
08/08/23
Buy
200,000$0.096$19,200On-market trade
NVU
Nanoveu Limited
16/06/23
Issued
2,000,000$0.024$48,000Issue of securities